dc.contributor.author | Judson, I | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Wong, NACS | |
dc.contributor.author | Dileo, P | |
dc.contributor.author | Bulusu, R | |
dc.contributor.author | Smith, M | |
dc.contributor.author | Almond, M | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-08-30T11:14:44Z | |
dc.date.available | 2024-08-30T11:14:44Z | |
dc.date.issued | 2024-06-05 | |
dc.identifier | 10.1038/s41416-024-02672-0 | |
dc.identifier.citation | British Journal of Cancer, 2024, | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6375 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/s41416-024-02672-0 | |
dc.identifier.doi | 10.1038/s41416-024-02672-0 | |
dc.description.abstract | BACKGROUND: British Sarcoma Group guidelines for the management of GIST were initially informed by those published by the European Society of Clinical Oncology. This update was written by a group of experts to includes a discussion of the highlight improvements in our knowledge of the disease and recent treatment developments. The guidelines include sections on Incidence, Aetiology, Diagnosis, including risk assessment, Treatment and Follow-up. METHODS: A careful review of the literature was performed to ensure that wherever possible recommendations are supported by the results of clinical trials or substantive retrospective reports. Areas of uncertainty are indicated appropriately. CONCLUSION: Guidelines represent a consensus view of current best clinical practice. Where appropriate, key recommendations are given and the levels of evidence and strength of recommendation gradings are those used by the European Society for Medical Oncology (ESMO). | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.relation.ispartof | British Journal of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | KINASE INHIBITOR THERAPY | |
dc.subject | PHASE-II TRIAL | |
dc.subject | IMATINIB MESYLATE | |
dc.subject | ADJUVANT IMATINIB | |
dc.subject | CARNEY-STRATAKIS | |
dc.subject | PROGRESSION-FREE | |
dc.subject | DOSE IMATINIB | |
dc.subject | RISK | |
dc.subject | MUTATIONS | |
dc.subject | DIAGNOSIS | |
dc.title | Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-03-25 | |
dc.date.updated | 2024-08-30T11:14:18Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41416-024-02672-0 | |
rioxxterms.licenseref.startdate | 2024-06-05 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38840030 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1038/s41416-024-02672-0 | |
icr.researchteam | Sarcoma Clinical Trials | |
icr.researchteam | Translational Sarcoma, Melanoma and Rare Tumour Surgery | |
dc.contributor.icrauthor | Smith, Myles | |
icr.provenance | Deposited by Mr Arek Surman on 2024-08-30. Deposit type is initial. No. of files: 1. Files: s41416-024-02672-0.pdf | |